Amivantamab is used as first treatment for adults with EGFR exon 20 insertion NSCLC as well as other EGFR mutations in NSCLC following development of resistance to EGFR tyrosine kinase inhibitors. Here, EGFR is linked to non-small cell lung carcinoma.